Verici Dx

The data to inform, the drive to earn trust.

Verici Dx partners with clinicians and their patients to offer a platform of single and related tests to improve patient care over the course of their transplant journey.

Learn More

An innovative path to better outcomes.

We are singularly focused on providing insights to inform the path to successful transplant outcomes for patients.

Learn More

Driven by curiosity. Delivered by science.

The drive to innovate and develop the suite of Verici Dx diagnostic products is spearheaded by our experienced molecular scientists and highly qualified bioinformaticians alongside AI machine learning technology...

Learn More

Next gen, next level.

Verici Dx is a developer of advanced clinical diagnostics in organ transplant based upon the patient’s own biological systems.

Learn More

A solid foundation.

Verici Dx products and solutions are underpinned by extensive scientific research enabled by access to expertly curated collaborative studies.

Learn More

We believe in partnerships.

Meaningful change happens through collaboration. Improving patient care takes a community. We champion groups devoted to collective, collaborative change.

Learn More

Tutivia ™

Tutivia™ is a next generation blood-based transcriptomic RNA signature designed to assess the risk of acute rejection in kidney transplant patients. Utilizing a proprietary algorithm powered by artificial intelligence, it generates a precise risk assessment score tailored to individual needs.

Tutivia™: Empowering Transplant Care with Precision.
VericiDx is excited to announce that our Tutivia validation study is available as open access in the March American Journal of Transplantation.

Tutivia is a patient-specific RNA expression blood test designed to detect changes earlier in the disease progression than conventional markers of injury.

Tutivia can be used as early as the first week after transplant, offering crucial insights for early monitoring and proactive management.

Tutivia delivers a patient-specific risk score that enables proactive management of your patients. It significantly outperforms serum creatinine in diagnosing acute rejection, achieving an AUC of 0.69 compared to serum creatinine’s AUC of 0.51.

Tutivia offers an easy-to-interpret risk score from 0 to 100, indicating low risk (≤50) or high risk (>50) based on the patient’s RNA signature.

When a Tutivia test indicates a high-risk result, the likelihood of the patient experiencing acute rejection is nearly 6 times higher compared to those with a low-risk result, further providing greater confidence in making informed clinical decisions.

Personalized Testing for Individualizing Care

Verici Dx kidney transplant tests utilize next-generation sequencing to create a personalized and precise risk profile for each patient throughout their transplant journey. From a simple blood draw, our tests not only assess individual risk but may also detect potential acute rejection before traditional clinical and pathological methods can
Tutivia Delivers

Please provide some basic information to access this content.